Illinois ties one death to vaping

A death in Illinois from pulmonary illness has been linked to the use of e-cigarettes, or vaping, according to the CDC. The Illinois patient is the first death reported amid an outbreak of lung illness that is somewhat mysterious but tied to vaping.

The report comes just days after the CDC announced it would help a handful of states investigate lung disease associated with e-cigarette use after 120 people across 15 states became injured.

The CDC held a call Aug. 23 to provide an update on the issue. As of Aug. 22, there were 193 potential cases in 22 states severe lung illness tied to vaping and e-cigarette use. While e-cigarettes have been noted to help smokers quit, the products can also damage blood vessels and cause other serious harms.

The CDC and states have not identified the cause of death, but there is no evidence of an infectious disease and cases have reported e-cigarette product use. Investigators from the agency also haven’t identified any specific product of compound linked to all the illnesses. Some patients have admitted to using THC––a chemical in marijuana––n their vaping products.

The agency also didn’t have much of an explanation for the recent surge in lung disease cases, noting that reported cases could have been occurring before the investigation began. The investigation is ongoing.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.